Human muscle-derived grafts for skeletal muscle repair and reconstruction.

Sarcogenics develops decellularized human skeletal muscle grafts designed to preserve the native extracellular matrix and structural characteristics of muscle tissue for use in skeletal muscle repair and reconstruction.

Advantages of the Decellularized Muscle Matrix

Our patent-pending Decellularized Muscle Matrix (DMM) recreates muscle’s natural extracellular environment, providing the structural and chemical cues necessary for healing.

Muscle-Specific Architecture

Derived from human skeletal muscle, DMM preserves key components and structural characteristics of the native muscle extracellular matrix.

Made for Muscle Repair

Unlike generalized soft-tissue scaffolds, DMM is being developed specifically for repair and reconstruction of skeletal muscle tissue.

Backed by Extensive Research

DMM technology is based on more than a decade of academic research at Virginia Commonwealth University evaluating muscle-derived extracellular matrices and their interaction with muscle, vascular, and neural tissues.

Sarcogenics Founder Michael McClure, Ph.D.

Our Research Plan

Sarcogenics is advancing our initial human muscle-derived graft toward commercialization while developing the tissue sourcing, processing, quality, and regulatory systems required for human tissue products.

How DMM Works

1

Remove cells while preserving structure

Donor skeletal muscle is carefully processed to remove cellular components while preserving the extracellular matrix and important structural characteristics of native muscle.

2

Preserve muscle-specific signals

The resulting graft retains the extracellular matrix composition and architecture characteristic of skeletal muscle tissue.

3

Repair muscle with muscle-derived tissue

DMM is designed for implantation at sites of skeletal muscle injury where a muscle-derived graft can provide tissue for repair, reconstruction, or replacement.

Gallery: DMM in development at the Sarcogenics lab

The Market Opportunity

Before Sarcogenics is a market that can transform the way physicians treat muscle-loss injuries. For interested investors, here’s a snapshot of the demand and revenue potential.

Initial Market: Military Trauma Treatment Facilities

Market Size: $7 billion

Annual Market Growth Rate: 6.7%

Investor information

Initial Product Platform: Human skeletal muscle-derived DMM for repair and reconstruction of skeletal muscle tissue.

Future / Next-Generation Research: Sarcogenics is also investigating next-generation approaches to complex muscle injury, including neuromuscular integration, cell-enabled technologies, and strategies designed to enhance functional recovery.

Our Team

  • Michael J. McClure, Ph.D.

    FOUNDER

  • Greg Merril

    CEO

  • Geetanjali Bendale, Ph.D.

    SCIENTIFIC ADVISER

  • Daniel Delgado, Ph.D. Candidate

    SCIENTIFIC ADVISER

  • Seema Sood

    BUSINESS ADVISER

  • Richard Pellegrino

    BUSINESS ADVISER

  • William Jeranek, M.D.

    CLINICAL ADVISER

The Science

Sarcogenics' technology platform originated from research at Virginia Commonwealth University examining how the native extracellular matrix of skeletal muscle influences tissue repair. The company's initial product development program focuses on decellularized human skeletal muscle tissue for skeletal muscle repair and reconstruction.

Next-Generation Research

Parallel research programs are exploring nerve integration, cellular approaches, and other technologies that could ultimately expand the potential of muscle reconstruction

Join us in transforming recovery from muscle injury. 

Sarcogenics is advancing our science with a clear path to commercialization. Contact us to learn how you can join us on this journey.